目的 探讨注射用丹参多酚酸治疗脑梗死急性期患者的疗效及对同型半胱氨酸（Hcy）、D-二聚体和超敏C反应蛋白（hs-CRP）水平影响。方法 选择2016年1月—2019年1月于安阳市第六人民医院收治的脑梗死急性期患者102例，随机分为对照组51例与治疗组51例。对照组患者常规治疗，治疗组在对照组基础上联用注射用丹参多酚酸（100 mg+250 mL的0.9%氯化钠溶液中，静脉滴注，1次/d）。两组疗程均为2周，比较两组疗效，治疗前后日常生活活动能力指数（Balthel指数）评分、蒙特利尔认知评估量表（MoCA）评分和神经功能缺损程度评分（NIHSS评分）变化，血清Hcy、D-二聚体和hs-CRP水平变化及不良反应。结果 治疗组治疗总有效率（92.16%）高于对照组（70.59%）（P<0.05）。治疗后，两组Balthel指数评分和MoCA评分较治疗前升高，而NIHSS评分较治疗前降低（P<0.05）；治疗组Balthel指数评分和MoCA评分高于对照组，而NIHSS评分低于对照组（P<0.05）。治疗后，两组血清Hcy、D-二聚体和hs-CRP水平较治疗前降低（P<0.05）；且治疗组血清Hcy、D-二聚体和hs-CRP水平低于对照组（P<0.05）。结论 注射用丹参多酚酸治疗脑梗死急性期患者疗效良好，可降低Hcy、D-二聚体和hs-CRP水平，值得临床借鉴。

Objective To investigate the therapeutic effect of Salvianolic Acids for Injection (SAFI) on acute cerebral infarction patients and its effects on the levels of homocysteine (Hcy), D-dimer and hypersensitive C-reactive protein (hs-CRP). Methods The 102 patients with acute cerebral infarction admitted to our hospital from January 2016 to January 2019 were divided into control group (51 cases) and treatment group (51 cases) according to random number table method. The control group received routine treatment, while the treatment group received intravenous drip of SAFI 100 mg+250 mL 0.9% sodium chloride solution once a day on the basis of the control group. Both groups were treated for 2 weeks. The therapeutic effects, the changes of Balthel index, Montreal Cognitive Assessment Scale (MoCA) and Neurological Deficiency Scale (NIHSS) before and after treatment, the changes of serum Hcy, D-dimer and hs-CRP levels, and the adverse reactions were compared between the two groups. Results The total effective rate of the treatment group (92.16%) was higher than that of the control group (70.59%) (P<0.05). After treatment, the Balthel index score and MoCA score of the two groups were higher than those before treatment, while the NIHSS score was lower than before treatment (P<0.05); after treatment, the Balthel index score and MoCA score of the treatment group were higher than those of the control group, while the NIHSS score was lower than that of the control group (P<0.05). After treatment, the levels of serum Hcy, D-dimer and hs-CRP in the two groups were lower than those before treatment (P<0.05); after treatment, the levels of serum Hcy, D-dimer and hs-CRP in the treatment group were lower than those in the control group (P<0.05). Conclusion SAFI is effective in the treatment of acute cerebral infarction. It can reduce the levels of Hcy, D-dimer and hs-CRP, which is worthy of clinical reference.

R969.4